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Abstract
Differentiated thyroid cancer is rarely associated with paraneoplastic events. Polymyositis, an
autoimmune inflammatory myopathy, can be manifested as a paraneoplastic syndrome (PS). We
report a case of a young woman who developed progressive proximal muscle weakness one and a
half year after a total thyroidectomy for papillary thyroid cancer. Clinical features, laboratory
results and muscle biopsy led us to the diagnosis of polymyositis, possibly related to her previous
malignancy. A search for recurrence of the thyroid carcinoma or other underlying malignancy was
fruitless. The patient improved slowly but almost completely after about 6 months of
immunosupressive therapy, which she is still receiving.
Background
Polymyositis (PM), along with dermatomyositis (DM),
are classified as idiopathic inflammatory myopathies
[1]predominantly affecting adults. Patients usually report
increasing difficulty with everyday tasks due to progressive
and often symmetric muscle weakness. The diagnosis is
based on a combination of clinical, laboratory and muscle
biopsy findings [2]. Both disorders may be linked with
malignancy, with DM patients facing a greater risk. We
present a case of a young woman who developed PM one
and a half year after thyroidectomy for a papillary thyroid
carcinoma. To date only two cases of papillary thyroid
cancer have been reported to be complicated with inflam-
matory myositis, specifically DM [3,4].
Case report
A 31 – year – old woman was admitted to our hospital
complaining of about 2-month duration myalgias of the
shoulder and neck muscles and progressive difficulty
combing her hair, climbing stairs, walking uphill and ris-
ing from a chair. She had no fever, arthralgia or arthritis,
cough, dyspnea, rash, difficulty with swallowing, par-
esthesias, abdominal pain, or other symptoms. Her phys-
ical examination was remarkable for 3/5 muscle strength
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in the upper and lower extremities confined to the proxi-
mal muscle groups. The tendon reflexes, muscular tone
and sensation were normal throughout and there were no
skin lesions. Chvostek's and Trousseau's sign were also
negative, as was the rest of the examination.
A prior diagnoses of Hashimoto thyroiditis (HT) was
made several years ago for which the patient did not
receive any medication. One and a half year ago the
patient was diagnosed with differentiated thyroid cancer
and treated with total thyroidectomy and regional neck
dissection. On histology, the tumor was a 3.5 cm papillary
cancer, showed a mainly follicular pattern of develop-
ment, capsule and vascular invasion. One of the seven dis-
sected regional nodes was also invaded by tumor cells.
The patient received hormone suppression with 225 μg of
levothyroxine daily with Thyroid Stimulating Hormone
(TSH) values ranging from 0.01 – 1 mU/L and six months
postoperatively, 100 mCi of 131I were administered for
thyroid remnant ablation, after preparation with a two-
dose regimen of recombinant human TSH. One year post-
operatively, a whole body scan with 5 mCi radiodine was
negative for residual or metastatic disease, while continu-
ing the aforementioned suppressive dose of levothyroxine
daily.
The patient did not smoke, drink alcohol or use illicit
drugs and her family history was negative for neuromus-
cular diseases.
At the present admission, laboratory investigation
showed a 40-fold elevation of plasma creatine kinase
(CK) level, as well as about 5-fold elevation of aldolase,
and 3-fold transaminase and lactic dehydrogenase (LDH)
levels. A mild hypocalcaemia was found (7.8 mg/dl, nor-
mal 8.1–10.2) with normal serum albumin (48 g/l).
Serum phosphorus was high-normal (4.5 mg/dl, normal
2.3–4.6), serum creatinine was 0.9 mg/dl, serum magne-
sium was low: 0.6 mmol/l (normal 0.7–1.1). Serum Par-
athyroid hormone was normal (23 pg/ml, normal 15–75)
and 25(OH) vitamin D was normal (30 nmol/l, normal
25–75). Antinuclear antibodies were detected in low titer
(1/80) with standard immunofluorescence, whereas the
myositis-specific antibody anti-Jo-1 and the ENAs were
negative. The anti-AchR antibodies were also negative.
The TSH level was < 0.01 mU/L.
A Magnetic resonance imaging (MRI) of the gluteal and
posterior femoral muscles was performed and revealed
increased signal intensity on T1 sequencing, attributed to
edema and/or inflammation [Figure 1].
The Electromyography (EMG) of upper and lower limbs
showed myopathic changes to all the examined proximal
muscles, e.g. short – duration, low-amplitude polyphasic
potentials and positive sharp waves, more prominent at
the pelvic girdle muscles.
Finally, we performed an open biopsy of her left deltoid
muscle (which was not tested with EMG), which on light
microscopy showed mild fiber atrophy and necrosis,
degeneration and regeneration, as well as an inflamma-
tory infiltrate composed mainly of CD4+ lymphocytes
scattered in between the muscle fibers and within the fas-
cicles. No evidence of vasculitis or other metabolic myop-
athy was detected and the dystrophin staining did not
detect dystrophic changes. Assessment with immunofluo-
rescence did not reveal any immune deposits at the skin or
muscle.
The patient was started on prednisone 0.5 mg/kg/d and
azathioprine 2 mg/kg/d along with calcium and vitamin
D supplementation. With the aim of localizing persistent
and/or recurring thyroid disease or a new underlying
malignancy, the patient was evaluated with whole body
radioiodine scan, neck ultrasound, chest X-ray, abdomi-
nal Computed tomography, transvaginal ultrasound and
mammography, with no evidence of disease. Her serum
thyroglobulin was < 0.1 ng/ml (normal range 0.1 – 1).
She improved very slowly but steadily and after about 6
months of slow tapering the prednisone was stopped
while continuing the same azathioprine dose. She had
regained almost normal muscular strength, along with
complete normalization of the muscle enzymes.
Magnetic resonance imaging (MRI) of the gluteal and poste- rior femoral muscles revealed increased signal intensity on  T1 sequencing, attributed to edema and inflammation Figure 1
Magnetic resonance imaging (MRI) of the gluteal and 
posterior femoral muscles revealed increased signal 
intensity on T1 sequencing, attributed to edema and 
inflammation. Along with MRI, electromyography and 
muscle biopsy findings were compatible with the diagnosis of 
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Discussion
Both PM and DM, as defined clinically, have prevalence
rates estimated at approximately one per 100,000 in the
general population. There is a female to male predomi-
nance of about 2:1. The peak incidence in adults occurs
between the ages of 40 and 50, but individuals of any age
may be affected [5]. Histologic features of DM and PM
include muscle fiber necrosis, degeneration and regenera-
tion, and inflammatory cell infiltration. In PM cellular
infiltrates are located predominantly within the fascicle,
consisting of cytotoxic CD8+ T-cells and macrophages,
whereas in DM, CD4+ T-cells, macrophages and B-cells
are found mainly perifasicular and often perivascular[1].
Furthermore in DM intravascular depositions of mem-
brane attack complex leads to perifascicular ischemic
lesions and subsequent reduction in the capillary density
[6,7]. The predominance of T CD4+ lymphocytes in the
muscular biopsy of our patient is not in favour of myosi-
tis, however the rest histological, laboratory and clinical
features appears to be highly supportive of the diagnosis
[2]
The major clinical manifestations of these inflammatory
myopathies are muscle weakness. In addition patients
with DM have characteristic skin lesions. Muscle weakness
is typically symmetric and predominantly proximal [8].
Elevations in serum CK, LDH, aldolase, and aminotrans-
ferases occur in most patients. In severe cases, the serum
CK concentration may be elevated 50-fold. Although a
correlation between the severity of the weakness and the
height of elevation in serum muscle enzymes may be seen,
the degree of muscle dysfunction may be much greater
than the enzyme levels would suggest [9]. Autoantibodies
are found in a majority of patients. Among the myositis-
specific antibodies, anti-histidyl-tRNA synthase antibod-
ies (eg, the anti-Jo-1 antibody) has been associated with
interstitial lung disease, Raynaud phenomenon, fever,
arthritis, and mechanic's hands, a syndrome known as the
anti-synthetase syndrome [10]. EMG shows evidence of
muscle irritability. EMG findings are helpful in confirm-
ing the presence of a myopathic process and in indicating
which muscle groups are most involved. This information
can be valuable in selecting a site for muscle biopsy. MRI
may be useful if physical examination and EMG fail to
identify a suitable target for muscle biopsy. MRI may also
be useful in the longitudinal follow-up of patients, as an
adjunct test to assess treatment responses and to diagnose
disease flares [11].
The association between the idiopathic inflammatory
myopathies and the development of malignancy has been
appreciated for nearly a century, but its meaning and sig-
nificance have remained unclear. Perhaps the most robust
data describing the link between myositis and malignancy
was published by Hill and colleagues [12] in 2001. The
authors identified 618 dermatomyositis and 914 polymy-
ositis patients. Cancer was detected in approximately 30%
of DM and 15% of PM patients, with over 60% of tumors
diagnosed after the diagnosis of myopathy. Both groups
were noted to have increased cancer risks compared with
the general population (standardized incidence ratio of
3.0 for DM, 1.4 for PM). The majority of cancers were
diagnosed within one year of the development of myosi-
tis, and as in previous observational studies, the most
common cancer types noted were adenocarcinomas,
which accounted for 70% of all associated tumors in both
DM and PM patients. Other studies have reported a fre-
quency of malignancy of 15 to 25 percent [13].
The spectrum of malignancies associated with DM or PM
parallels the distribution in the general population with
the possible exceptions of an increased frequency of cervi-
cal, lung, ovarian, pancreatic, bladder, and gastric carcino-
mas, and with non-Hodgkin lymphoma [12-14].
Cancer can be diagnosed before, at the time of, or after the
diagnosis of myositis with a peak incidence occurring
within the two year period before and after the develop-
ment of myositis [14]. Also, in some patients, the myositis
is first diagnosed at a time of recurrence of a previously
diagnosed cancer, while in others the myositis reactivates
at a time when the cancer first becomes obvious [15].
Our patient was diagnosed with PM based on clinical
presentation, elevated CK and muscle biopsy results. Thy-
roid cancer preceded the development of PM in our case,
and this temporal relation suggests a PS, however due to
the absence of paraneoplastic antibodies a firm diagnosis
is difficult to be made. Nevertheless according to Graus F.
et al [16], PM, a "nonclassical" paraneoplastic neurologic
syndrome in that study, is possibly paraneoplastic, even if
"well-characterized" paraneoplastic antibodies (anti-Hu,
CV2, Ri, Ma2, and amphiphysin) are absent, provided
that it occurs within two years of malignancy. Further-
more, since PSs are considered to be immune mediated
perhaps the presence of a prior medical history of HT, a
well-known autoimmune disorder [17], could act as a
promoting factor indicating a deranged immunological
background.
In conclusion, this is the first report of PM associated with
differentiated thyroid cancer. Awareness of a potential PM
complication is important because it can be confused with
other causes of muscle weakness in the case of malignancy
and/or after a thyroidectomy – such as myasthenic syn-
dromes, hypothyroidism, hypocalcemic myopathy, etc.-
and because prompt diagnosis of PM with early initiation
of steroid and immunosuppressive therapy in such a clin-
ical setting may avoid subsequent sequel.Publish with BioMed Central    and   every 
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